Cosmos Health (COSM) has entered into an extension of its existing exclusive distribution agreement with Virax Biolabs (VRAX) to commercialize mpox virus real-time PCR detection kits in countries within the Gulf Cooperation Council. It had previously signed an agreement for exclusive distribution in Greece and Cyprus, as well as for non-exclusive distribution throughout Europe. Under the agreement, Cosmos Health is now also authorized to import, sell, and distribute Virax-branded mpox Virus Nucleic Acid Detection Kits throughout the GCC, including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. The RT-PCR mpox virus detection kits are CE-marked for sale in Europe and authorized by the UK’s Medicines and Healthcare products Regulatory Agency. These tests offer a sensitivity of 96.7% and a specificity of 93.72%, providing results in under 70 minutes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COSM:
- Cosmos Health regains Nasdaq compliance
- Cosmos’ Cana completes facility upgrades, secures manufacturing agreement
- Cosmos Health reports Q1 EPS (11c) vs. (4c) last year
- Cosmos Health reports FY23 EPS ($2.15) vs. ($33.16) last year
- Cosmos Health’s Cana completes Phase 1 of production capacity expansion